Physician profile
Amanda E Butler
NPI 1508314279
$2,667.07
in general payments reported to CMS, 2019-2025
25 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $147 · 2023: $786 · 2024: $357 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $360.90 | 2022-2025 | Urolift, Barrigel |
| Pfizer INC. | $332.72 | 2025 | |
| Endo Pharmaceuticals INC. | $277.07 | 2022-2024 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $214.78 | 2023-2025 | Gemtesa |
| Saluda Medical Americas, INC. | $206.24 | 2025 | Evoke |
| Globus Medical, INC. | $168.49 | 2025 | Senza |
| Medtronic, INC. | $162.39 | 2023-2025 | Interstim |
| Abbvie INC. | $142.39 | 2023-2025 | |
| Abbott Laboratories | $132.75 | 2025 | Eterna, Proclaim |
| Axonics, INC. | $115.97 | 2023-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $71.19 | 2023-2024 | Veozah, Myrbetriq |
| Urovant Sciences INC | $61.32 | 2022 | |
| Boston Scientific Corporation | $60.15 | 2023-2025 | Ams 700, Spaceoar Vue System - 10ml |
| Tolmar, INC. | $53.00 | 2023-2025 | Eligard |
| Accord Healthcare, INC. | $47.80 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $39.99 | 2025 | |
| Procept Biorobotics Corporation | $37.68 | 2024 | Aquabeam System |
| Novartis Pharmaceuticals Corporation | $33.56 | 2025 | |
| Curonix LLC | $26.65 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Telix Pharmaceuticals | $22.40 | 2025 | Illuccix |
| Urogen Pharma, INC. | $21.00 | 2023 | |
| Averitas Pharma INC. | $20.81 | 2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $20.29 | 2025 | Xtampza |
| Valinor Pharma, LLC | $20.13 | 2025 | Movantik |
| Verity Pharmaceuticals INC. | $17.40 | 2024 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.